Literature DB >> 11472395

Enhancement of cALL immunogenicity by co-culture with a CD154 expressing 293 cell line.

A J Lee1, C Haworth, R M Hutchinson, R Patel, R Carter, R F James.   

Abstract

Pre-B cell acute lymphoblastic leukaemia (cALL) commonly occurs in young patients and although successful conventional therapies are available (such as cytotoxic drugs and bone marrow transplantation) for a proportion of patients (approximately 30%) these are ultimately unsuccessful. Recurrence of disease is a result of the failure of the immune system to recognize these abnormal cells and down-regulation of crucial molecules required for cognate CD4(+) T cell recognition has been postulated as a means of immune escape. In this study we show that an embryonic kidney cell line (293 cells) transfected with CD154 (40 L.1) are capable of not only maintaining the viability of primary ALL cells in culture but can also up-regulate the expression of a number of crucial molecules involved in antigen recognition. We show that 40 L.1 cell stimulation of primary ALL cell cultures can not only enhance the allogeneic and autologous MLR response to such cells but will also induce CTL effectors which are capable of lysing wild-type autologous ALL cells. It is therefore conceivable that such an approach could be used to generate an active anti-tumour response in patients, following conventional therapy, reducing the incidence of recurrence.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11472395      PMCID: PMC1906064          DOI: 10.1046/j.1365-2249.2001.01562.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  36 in total

1.  CD40-activated B-cell chronic lymphocytic leukemia cells for tumor immunotherapy: stimulation of allogeneic versus autologous T cells generates different types of effector cells.

Authors:  R Buhmann; A Nolte; D Westhaus; B Emmerich; M Hallek
Journal:  Blood       Date:  1999-03-15       Impact factor: 22.113

2.  A cell culture model for T lymphocyte clonal anergy.

Authors:  R H Schwartz
Journal:  Science       Date:  1990-06-15       Impact factor: 47.728

3.  Intercellular adhesion molecule 1 (ICAM-1) has a central role in cell-cell contact-mediated immune mechanisms.

Authors:  A W Boyd; S O Wawryk; G F Burns; J V Fecondo
Journal:  Proc Natl Acad Sci U S A       Date:  1988-05       Impact factor: 11.205

Review 4.  The costimulatory function of antigen-presenting cells.

Authors:  C T Weaver; E R Unanue
Journal:  Immunol Today       Date:  1990-02

Review 5.  T-cell clonal anergy.

Authors:  R H Schwartz; D L Mueller; M K Jenkins; H Quill
Journal:  Cold Spring Harb Symp Quant Biol       Date:  1989

Review 6.  Antigen processing for presentation to T lymphocytes: function, mechanisms, and implications for the T-cell repertoire.

Authors:  J A Berzofsky; S J Brett; H Z Streicher; H Takahashi
Journal:  Immunol Rev       Date:  1988-12       Impact factor: 12.988

7.  B7, a B-cell-restricted antigen that identifies preactivated B cells.

Authors:  A S Freedman; G Freeman; J C Horowitz; J Daley; L M Nadler
Journal:  J Immunol       Date:  1987-11-15       Impact factor: 5.422

8.  A theory of self-nonself discrimination.

Authors:  P Bretscher; M Cohn
Journal:  Science       Date:  1970-09-11       Impact factor: 47.728

9.  The function of human intercellular adhesion molecule-1 (ICAM-1) in the generation of an immune response.

Authors:  G J Dougherty; S Murdoch; N Hogg
Journal:  Eur J Immunol       Date:  1988-01       Impact factor: 5.532

10.  Downregulation of cell adhesion molecules LFA-3 and ICAM-1 in Epstein-Barr virus-positive Burkitt's lymphoma underlies tumor cell escape from virus-specific T cell surveillance.

Authors:  C D Gregory; R J Murray; C F Edwards; A B Rickinson
Journal:  J Exp Med       Date:  1988-06-01       Impact factor: 14.307

View more
  1 in total

1.  Microtube Array Membrane Hollow Fiber Assay (MTAM-HFA)-An Accurate and Rapid Potential Companion Diagnostic and Pharmacological Interrogation Solution for Cancer Immunotherapy (PD-1/PD-L1).

Authors:  Wan-Ting Huang; Tsao Yun; Chee-Ho Chew; Amanda Chen; Po-Li Wei; Kang-Yun Lee; Hsin-Lun Lee; Po-Hao Feng; Jeng-Fong Chiou; Ching-Mei Chen; Chien-Chung Chen
Journal:  Biomolecules       Date:  2022-03-22
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.